38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) from ALTA-1L

A. Delmonte,M-J. Ahn, S. Ghosh, M.J. Hochmair,T-Y. Yang,J.C-H. Yang,J-Y. Han, K.H. Holmskov,Y. Wu, Y. Wan, M. Lin, J. Kretz, B. Hupf, A.M. Kurec, E. Churchill, R. Fram, C.J. Cabasag, V. Goriya,Y. Zhao,M.R. García Campelo

ESMO Open(2024)

引用 0|浏览2
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要